Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: ixhl), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial updates, patent disclosures, and convertible-note financing details make Incannex Healthcare’s SEC documents uniquely dense. If you have ever searched for “Incannex Healthcare SEC filings explained simply,” you know how hard it is to decode cannabinoid and psychedelic trial data buried across dozens of forms.
Stock Titan solves this by pairing real-time EDGAR feeds with AI that translates technical jargon into clear language. Whether you need the “Incannex Healthcare quarterly earnings report 10-Q filing” (or its foreign filer equivalent), “Incannex Healthcare insider trading Form 4 transactions,” or an “Incannex Healthcare 8-K material events explained,” our platform surfaces the line items that move markets. Key features include:
- Instant alerts for “Incannex Healthcare Form 4 insider transactions real-time” and “Incannex Healthcare executive stock transactions Form 4.”
- AI-powered summaries of trial milestones inside 6-K/8-K releases and the “Incannex Healthcare earnings report filing analysis.”
- Side-by-side comparisons that make the “Incannex Healthcare annual report 10-K simplified” (and 20-F equivalents) readable in minutes.
- Easy access to the “Incannex Healthcare proxy statement executive compensation” so you can see how leadership is rewarded as new therapies progress.
Use our expert analysis to track segment spending on obstructive sleep apnea trials, monitor licensing revenue, and benchmark R&D burn—without parsing hundreds of pages manually. Understanding Incannex Healthcare SEC documents with AI lets you spot insider confidence before material announcements, compare quarter-over-quarter cash usage, and act on data that matters. Complex biotech filings, clarified.
Incannex Healthcare Inc. will hold its 2025 annual meeting in a hybrid format at 10:00 a.m. Gulf Standard Time on December 18, 2025, with virtual access and an in‑person option in Dubai.
Stockholders are asked to elect two Class II directors—Dr. George Anastassov and Robert Clark—for three-year terms ending in 2028, and to ratify Grant Thornton Audit Pty Ltd as independent registered public accounting firm for the fiscal year ending June 30, 2026. The board recommends approval of both proposals.
Holders of common stock at the close of business on October 24, 2025 may vote. Shares outstanding were 347,705,507 as of that date. Director elections will be decided by a plurality of votes cast; auditor ratification requires a majority of voting power present and entitled to vote.
Incannex Healthcare (IXHL)
The company reported this under Item 8.01 on October 22, 2025. Further details are available in a press release furnished as Exhibit 99.1.
Incannex Healthcare (IXHL) reported a Nasdaq compliance update. The company received a second 180-day grace period, until April 20, 2026, to regain compliance with Nasdaq’s $1.00 minimum bid price rule. The extension follows IXHL’s July transfer from the Nasdaq Global Market to the Nasdaq Capital Market, where it meets all initial listing standards except the bid price requirement.
IXHL can regain compliance if its closing bid price is at least $1.00 for 10 consecutive business days, which Nasdaq may extend to 20 days at its discretion. The company stated it intends to cure the deficiency, including by effecting a reverse stock split if necessary. IXHL’s shares continue to trade on the Nasdaq Capital Market while it remains subject to the market’s other continued listing requirements.
Incannex Healthcare Inc. (IXHL) is an R&D-focused clinical-stage company developing three lead drug candidates: IHL-42X (for obstructive sleep apnea), PSX-001 (psilocybin-based therapy) and IHL-675A (inflammatory and autoimmune indications). Clinical data disclosed for IHL-42X show statistically significant reductions in AHI versus placebo (maximum reductions up to 83% high-dose, 79% low-dose) and clinically meaningful improvements in patient-reported outcomes including fatigue and sleep impairment. Financially the company reported continuing operating losses ($23.8M loss from operations) and net cash outflows from operations (~$12.5M for FY 2025). The company raised gross proceeds of ~$12.5M from an equity offering (9.687M shares at $1.08) and undertook financings, debenture repayments and warrant cancellations during the year. Material risks highlighted include dependence on R&D tax incentives, need for DEA scheduling and FDA/other regulatory approvals, potential listing risk on Nasdaq, and ongoing cash requirements to advance pivotal programs.
Incannex Healthcare Inc. (Nasdaq: IXHL) filed a Form 8-K on 8 Aug 2025 announcing that it has received “positive patient-reported outcomes and compelling Phase 2 efficacy data” for IHL-42X, its drug candidate for obstructive sleep apnoea (OSA). The disclosure is provided via a press release attached as Exhibit 99.1 and incorporated under Item 8.01; no financial statements or other quantitative information accompany the notice. The report, signed by CEO Joel Latham, signals meaningful clinical progress for a core pipeline asset but leaves key metrics—statistical significance, safety profile and regulatory timeline—undisclosed. Investors must consult the referenced press release for comprehensive data and next-step development plans.
FAQ
What is the current stock price of Incannex Healthcare (ixhl)?
What is the market cap of Incannex Healthcare (ixhl)?
